Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned
Search Results for: Walder Wyss
ASMALLWORLD has successfully completed a capital increase a few days ago. Investors subscribed all of the 2.742.742 new shares, which will be traded on the SIX Swiss Exchange. As part of the capital increase, a large
Over the past years, Capture Media has played a significant role in shaping the landscape of Engagement Advertising in Switzerland, becoming an essential quality factor for many online campaigns. The company has also introduced fusedeck,
Syz Capital, a specialist for investments in private markets, together with its operating partner Saturnus Capital, a Swiss private equity firm focused on transactions in the SME sector, are investing in Capture Media, an
CONVOTIS has acquisted JMC Group and is entering the Swiss IT market as a platform company and strengthening its position in the managed services and digital platform solutions segment. This acquisition not only provides an
Walder Wyss has acted as legal counsel to SkyCell on the completion of a USD 57 million equity financing round at a USD 600 million valuation with M&G Investments, a global investment firm that invests
Coopers Group, a Swiss personnel service provider in the field of professional and executive search, has successfully acquired Zurich-based iET Group, which draws on many years of expertise in recruitment processes. This strategic acquisition is
Walder Wyss has incorporated four new counsels to the firm: Stefan Walder, Iliana Djagova, Joy Malka and Téo Genecand (photographed in order of mention). Stefan Walder is counsel in the corporate/M&A
In early October UBS has published the Base Prospectus for the establishment of its CHF 20 bn program for the issuance of Covered Bonds issued by UBS Switzerland and guaranteed by UBS Hypotheken Schweiz. The
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
